NASDAQ:PMVP PMV Pharmaceuticals (PMVP) Stock Forecast, Price & News $6.14 +0.11 (+1.82%) (As of 02:03 PM ET) Add Compare Share Share Today's Range$5.91▼$6.2850-Day Range$6.03▼$8.9352-Week Range$3.84▼$13.02Volume125,939 shsAverage Volume486,544 shsMarket Capitalization$297.54 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media PMV Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside262.4% Upside$22.00 Price TargetShort InterestBearish18.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 2 Articles This WeekInsider TradingSelling Shares$27,168 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.67) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 starsMedical Sector923rd out of 963 stocksPharmaceutical Preparations Industry432nd out of 451 stocks 3.5 Analyst's Opinion Consensus RatingPMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, PMV Pharmaceuticals has a forecasted upside of 262.4% from its current price of $6.07.Amount of Analyst CoveragePMV Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.41% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.Change versus previous monthShort interest in PMV Pharmaceuticals has recently increased by 15.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPMV Pharmaceuticals does not currently pay a dividend.Dividend GrowthPMV Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMVP. Previous Next 2.1 News and Social Media Coverage News SentimentPMV Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PMV Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,168.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of PMV Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PMV Pharmaceuticals is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMV Pharmaceuticals is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMV Pharmaceuticals has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PMV Pharmaceuticals (NASDAQ:PMVP) StockPMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.Read More PMVP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMVP Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comPMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsAugust 30, 2023 | finance.yahoo.comWall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a BetSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 29, 2023 | finance.yahoo.comPMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden CrossAugust 11, 2023 | msn.comHC Wainwright & Co. Maintains PMV Pharmaceuticals (PMVP) Buy RecommendationAugust 9, 2023 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate HighlightsAugust 9, 2023 | finance.yahoo.comPMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate HighlightsJune 20, 2023 | finance.yahoo.comPMVP Jul 2023 5.000 callSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."June 10, 2023 | morningstar.comPMV Pharmaceuticals Inc Ordinary SharesMay 17, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for PMV PharmaMay 17, 2023 | msn.comHC Wainwright & Co. Reiterates PMV Pharmaceuticals (PMVP) Buy RecommendationMay 12, 2023 | msn.comOppenheimer Reiterates PMV Pharmaceuticals (PMVP) Outperform RecommendationMay 11, 2023 | marketwatch.com8-K: PMV Pharmaceuticals, Inc.May 10, 2023 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate HighlightsMay 10, 2023 | finance.yahoo.comPMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate HighlightsMarch 27, 2023 | msn.comWall Street’s 10 most shorted stocks right now, including Silvergate and WeWorkMarch 20, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for PMV Pharmaceuticals (PMVP)March 1, 2023 | benzinga.comPMV Pharmaceuticals shares are trading lower after the company reported FY22 financial results.March 1, 2023 | finance.yahoo.comPMV Pharmaceuticals to Participate at Upcoming Investor Conferences in MarchMarch 1, 2023 | finance.yahoo.comPMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate HighlightsFebruary 22, 2023 | finance.yahoo.comVeterinary Pharmaceuticals Global Market Opportunities And Strategies To 2031February 17, 2023 | nasdaq.comRtw Investments Now Owns 9.50% of PMV Pharmaceuticals (PMVP)December 8, 2022 | finance.yahoo.comDoes PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?November 22, 2022 | finance.yahoo.comPMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceNovember 8, 2022 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate HighlightsNovember 8, 2022 | finance.yahoo.comPMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate HighlightsSee More Headlines Receive PMVP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PMVP Company Calendar Last Earnings8/09/2023Today9/27/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PMVP CUSIPN/A CIK1699382 Webwww.pmvpharma.com Phone609-642-6670FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.00 High Stock Price Forecast$29.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+264.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.05% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio16.63 Quick Ratio16.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.39 per share Price / Book1.12Miscellaneous Outstanding Shares48,460,000Free Float44,772,000Market Cap$292.21 million OptionableNot Optionable Beta0.93 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. David H. Mack Ph.D. (Age 61)Co-Founder, CEO, Pres & Director Comp: $762.02kDr. Arnold J. Levine Ph.D. (Age 83)Co-Founder, Director & Member of Scientific Advisory Board Comp: $140kMr. Winston Kung M.B.A. (Age 47)COO & CFO Comp: $591.29kDr. Leila Alland M.D. (Age 60)Chief Medical Officer Comp: $601.93kDr. Thomas E. Shenk Ph.D. (Age 76)Co-Founder & Member of Scientific Advisory Board Mr. Robert Ticktin (Age 61)Gen. Counsel & Company Sec. Mr. Tim SmithSr. VP & Head of Corp. Devel.Ms. Crystal ZuckermanVP of HRDr. Binh Vu Ph.D.Sr. VP of Drug Discovery & CMCDr. Deepika Jalota Pharm.D. (Age 46)Chief Devel. Officer More ExecutivesKey CompetitorsNanobiotixNASDAQ:NBTXSilence TherapeuticsNASDAQ:SLNSeres TherapeuticsNASDAQ:MCRBMacroGenicsNASDAQ:MGNXNuvation BioNYSE:NUVBView All CompetitorsInsiders & InstitutionsDeepika JalotaSold 4,104 sharesTotal: $27,168.48 ($6.62/share)California State Teachers Retirement SystemSold 18,868 shares on 8/21/2023Ownership: 0.026%Alliancebernstein L.P.Bought 2,590 shares on 8/15/2023Ownership: 0.101%Fishman Jay A Ltd. MIBought 5,000 shares on 8/15/2023Ownership: 0.062%Royal Bank of CanadaBought 1,957 shares on 8/15/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions PMVP Stock - Frequently Asked Questions Should I buy or sell PMV Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PMVP shares. View PMVP analyst ratings or view top-rated stocks. What is PMV Pharmaceuticals' stock price forecast for 2023? 2 analysts have issued 1 year price objectives for PMV Pharmaceuticals' stock. Their PMVP share price forecasts range from $15.00 to $29.00. On average, they expect the company's share price to reach $22.00 in the next year. This suggests a possible upside of 264.8% from the stock's current price. View analysts price targets for PMVP or view top-rated stocks among Wall Street analysts. How have PMVP shares performed in 2023? PMV Pharmaceuticals' stock was trading at $8.70 at the start of the year. Since then, PMVP shares have decreased by 30.7% and is now trading at $6.03. View the best growth stocks for 2023 here. When is PMV Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our PMVP earnings forecast. How were PMV Pharmaceuticals' earnings last quarter? PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09. What ETFs hold PMV Pharmaceuticals' stock? ETFs with the largest weight of PMV Pharmaceuticals (NASDAQ:PMVP) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).IQ Chaikin U.S. Small Cap ETF (CSML). What other stocks do shareholders of PMV Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE). When did PMV Pharmaceuticals IPO? (PMVP) raised $126 million in an initial public offering on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO. What is PMV Pharmaceuticals' stock symbol? PMV Pharmaceuticals trades on the NASDAQ under the ticker symbol "PMVP." Who are PMV Pharmaceuticals' major shareholders? PMV Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.22%), JPMorgan Chase & Co. (8.90%), Principal Financial Group Inc. (2.02%), Geode Capital Management LLC (1.63%), Woodline Partners LP (1.51%) and Bank of Montreal Can (1.53%). Insiders that own company stock include Arnold J Levine, Arnold J Levine, David Henry Mack, Deepika Jalota, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Orbimed Advisors Llc, Paul Klauder, Ra Capital Management, LP, Richard A Heyman, Thilo Schroeder and Winston Kung. View institutional ownership trends. How do I buy shares of PMV Pharmaceuticals? Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PMV Pharmaceuticals' stock price today? One share of PMVP stock can currently be purchased for approximately $6.03. How much money does PMV Pharmaceuticals make? PMV Pharmaceuticals (NASDAQ:PMVP) has a market capitalization of $292.21 million. The company earns $-73,320,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. How can I contact PMV Pharmaceuticals? The official website for the company is www.pmvpharma.com. The company can be reached via phone at 609-642-6670 or via email at investors@pmvpharma.com. This page (NASDAQ:PMVP) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.